- Home
- NERV vs GROW Comparison
NERV vs GROW Comparison
Compare NERV & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NERV | GROW |
|---|---|---|
| Founded | 2007 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 32.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | NERV | GROW |
|---|---|---|
| Price | $4.71 | $2.45 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 45.9K | 34.5K |
| Earning Date | 02-24-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 3.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $8,546,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $2.02 |
| 52 Week High | $12.46 | $2.78 |
Technical Indicators
Market Signals| Indicator | NERV | GROW |
|---|---|---|
| Relative Strength Index (RSI) | 67.06 | 55.82 |
| Support Level | $3.82 | $2.39 |
| Resistance Level | $4.24 | $2.55 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 89.56 | 69.80 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.